|
End-of-day quote
Taiwan S.E.
10/09/2026
|
5-day change | 1st Jan Change | ||
| 46.45 TWD | +1.42% |
|
+0.98% | -21.67% |
| Market Cap | 5.59B 176M 152M 143M 130M 244M 16.87B 246M 1.71B 656M 8.56B 663M 648M 27.18B | P/E 2024 |
52.9x | P/E 2025 | 16.3x |
|---|---|---|---|---|---|
| Enterprise Value | 6.7B 212M 182M 172M 156M 293M 20.24B 295M 2.05B 787M 10.27B 795M 778M 32.61B | EV / Sales 2024 |
2x | EV / Sales 2025 | 1.7x |
| Free-Float |
78.86% | Yield 2024 |
4.36% | Yield 2025 | 5.06% |
| 1 day | +1.42% | ||
| 1 week | +0.98% | ||
| Current month | -4.72% | ||
| 1 month | -14.61% | ||
| 3 months | -10.33% | ||
| 6 months | -10.15% | ||
| Current year | -21.67% |
| 1 week | 45.15 |  | 46.7 |
| 1 month | 45 | | 55.5 |
| Current year | 45 | | 62.5 |
| 1 year | 45 | | 68.7 |
| 3 years | 45 | | 121 |
| 5 years | 44.2 | | 121 |
| 10 years | 29.75 | | 121 |
| Manager | Title | Age | Since |
|---|---|---|---|
Cheng Yue Cheng
CEO | Chief Executive Officer | - | 31/12/1995 |
Yue Chen Lo
DFI | Director of Finance/CFO | - | 13/04/2003 |
Chin Yuan Lin
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Cheng Yue Cheng
CHM | Chairman | - | 31/12/1995 |
Che Jen Chuang
BRD | Director/Board Member | - | 17/06/2012 |
Hung Min Hsieh
BRD | Director/Board Member | - | 27/08/2006 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.42% | +0.98% | -30.98% | -48.39% | 176M | |
| -0.11% | -3.16% | +48.82% | +91.49% | 1,001B | |
| -0.27% | -4.34% | +51.52% | +65.89% | 642B | |
| +1.63% | -2.00% | +20.49% | +71.12% | 451B | |
| +0.32% | -3.25% | +28.69% | +36.04% | 340B | |
| +0.73% | -12.95% | +10.83% | +27.73% | 263B | |
| +0.34% | -1.78% | -1.37% | +12.28% | 247B | |
| -2.25% | -13.88% | +37.33% | +47.43% | 207B | |
| -2.91% | -6.91% | -19.56% | -59.31% | 197B | |
| -0.58% | -4.24% | +25.65% | +90.54% | 180B | |
| Average | -0.10% | -4.73% | +17.14% | +33.48% | 352.65B | |
| Weighted average by Cap. | +0.04% | -4.65% | +31.73% | +57.53% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 4.73B 149M 129M 121M 110M 207M 14.29B 208M 1.44B 556M 7.25B 561M 549M 23.02B | 4.85B 153M 132M 124M 113M 212M 14.65B 214M 1.48B 570M 7.43B 575M 563M 23.6B |
| Net income | 157M 4.97M 4.27M 4.03M 3.67M 6.86M 475M 6.93M 48.01M 18.48M 241M 18.66M 18.25M 765M | 441M 13.93M 11.98M 11.31M 10.3M 19.25M 1.33B 19.43M 135M 51.82M 676M 52.32M 51.18M 2.15B |
| Net Debt | 1.2B 37.78M 32.49M 30.65M 27.93M 52.2M 3.61B 52.68M 365M 141M 1.83B 142M 139M 5.82B | 1.12B 35.24M 30.3M 28.59M 26.05M 48.69M 3.37B 49.13M 341M 131M 1.71B 132M 129M 5.43B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/09/26 | NT$46.45 | +1.42% | 524,866 |
| 09/09/26 | NT$45.80 | +0.55% | 470,788 |
| 08/09/26 | NT$45.55 | -1.83% | 823,677 |
| 07/09/26 | NT$46.40 | +2.32% | 862,577 |
| 04/09/26 | NT$45.35 | -1.41% | 856,389 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4746 Stock
Select your edition
All financial news and data tailored to specific country editions
